Related Experiment Video
Updated: Nov 28, 2025

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
Determining the prognostic significance of IKKα in prostate cancer
Melania Montes1, Lewis MacKenzie2, Milly J McAllister1
1Unit of Gastrointestinal and Molecular Pathology, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, Institute of Cancer Science, University of Glasgow, Glasgow, UK.
Background:
As the survival of castration-resistant prostate cancer (CRPC) remains poor, and the nuclear factor-κB (NF-κB) pathways play key roles in prostate cancer (PC) progression, several studies have focused on inhibiting the NF-κB pathway through generating inhibitory κB kinase subunit α (IKKα) small molecule inhibitors. However, the identification of prognostic markers able to discriminate which patients could benefit from IKKα inhibitors is urgently required. The present study investigated the prognostic value of IKKα, IKKα phosphorylated at serine 180 (p-IKKα S180) and threonine 23 (p-IKKα T23), and their relationship with the androgen receptor (AR) and Ki67 proliferation index to predict patient outcome.
Methods:
A cohort of 115 patients with hormone-naïve PC (HNPC) and CRPC specimens available were used to assess tumor cell expression of proteins within both the cytoplasm and the nucleus by immunohistochemistry. The expression levels were dichotomized (low vs high) to determine the associations between IKKα, AR, Ki67, and patients'Isurvival. In addition, an analysis was performed to assess potential IKKα associations with clinicopathological and inflammatory features, and potential IKKα correlations with other cancer pathways essential for CRPC growth.
Results:
High levels of cytoplasmic IKKα were associated with a higher cancer-specific survival in HNPC patients with low AR expression (hazards ratio [HR], 0.33; 95% confidence interval [CI] log-rank, 0.11-0.98; P = .04). Furthermore, nuclear IKKα (HR, 2.60; 95% CI, 1.27-5.33; P = .01) and cytoplasmic p-IKKα S180 (HR, 2.10; 95% CI, 1.17-3.76; P = .01) were associated with a lower time to death from recurrence in patients with CRPC. In addition, high IKKα expression was associated with high levels of T-cells (CD3+ P = .01 and CD8+ P = .03) in HNPC; however, under castration conditions, high IKKα expression was associated with high levels of CD68+ macrophages (P = .04), higher Gleason score (P = .01) and more prostate-specific antigen concentration (P = .03). Finally, we identified crosstalk between IKKα and members of the canonical NF-κB pathway in the nucleus of HNPC. Otherwise, IKKα phosphorylated by noncanonical NF-κB and Akt pathways correlated with members of the canonical NF-κB pathway in CRPC.
Conclusion:
The present study reports that patients with CRPC expressing high levels of nuclear IKKα or cytoplasmic p-IKKα S180, which associated with a lower time to death from recurrence, may benefit from IKKα inhibitors.
Insights
High nuclear IKKα or cytoplasmic p-IKKα S180 levels in castration-resistant prostate cancer (CRPC) indicate a poorer prognosis. These findings suggest patients with these markers may benefit from IKKα inhibitors for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Castration-resistant prostate cancer (CRPC) survival is poor, with nuclear factor-κB (NF-κB) pathways driving progression.
- Inhibiting the NF-κB pathway via inhibitory κB kinase subunit α (IKKα) small molecule inhibitors is a therapeutic focus.
- Identifying prognostic markers for IKKα inhibitor efficacy in CRPC patients is crucial.
Purpose of the Study:
- To investigate the prognostic value of IKKα, phosphorylated IKKα (p-IKKα S180 and p-IKKα T23), and their relationship with androgen receptor (AR) and Ki67.
- To predict patient outcomes in hormone-naïve prostate cancer (HNPC) and CRPC based on IKKα expression.
- To explore associations between IKKα and clinicopathological/inflammatory features in prostate cancer.
Main Methods:
- Immunohistochemistry was used to assess IKKα, p-IKKα S180, p-IKKα T23, AR, and Ki67 expression in 115 HNPC and CRPC patient specimens.
- Protein expression levels were dichotomized (low vs. high) to analyze associations with survival and clinicopathological features.
- Correlations between IKKα and inflammatory markers (T-cells, macrophages) and other cancer pathways were investigated.
Main Results:
- High cytoplasmic IKKα correlated with better survival in HNPC patients with low AR expression (HR, 0.33; P=.04).
- Nuclear IKKα (HR, 2.60; P=.01) and cytoplasmic p-IKKα S180 (HR, 2.10; P=.01) were associated with decreased survival in CRPC patients.
- IKKα expression correlated with immune cell infiltration (CD3+, CD8+, CD68+), higher Gleason scores, and increased PSA levels in CRPC.
Conclusions:
- High nuclear IKKα or cytoplasmic p-IKKα S180 levels in CRPC patients predict a shorter time to death from recurrence.
- These findings suggest that patients with high nuclear IKKα or cytoplasmic p-IKKα S180 may benefit from IKKα inhibitors.
- IKKα plays a complex role in prostate cancer progression, interacting with AR, proliferation, and inflammatory pathways.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway

